Prdm5 suppresses Apc Min-driven intestinal adenomas and regulates monoacylglycerol lipase expression

Oncogene

Volumn 33, Issue 25, 2014, Pages 3342-3350

  Galli, G G ^a,g,h   Multhaupt, H A ^b   Carrara, M ^c   De Lichtenberg, K H ^a   Christensen, I B J ^d   Linnemann, D ^e   Santoni Rugiu, E ^f   Calogero, R A ^c   Lund, A H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

^e GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^f Department of Pathology Diagnostic Center Righospitalet   (Denmark)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h Harvard University   (United States)

Author keywords

adenoma; APC; intestinal cancer; PRDM5

Indexed keywords

ACYLGLYCEROL LIPASE; APC PROTEIN; PROTEIN PRDM5; TRANSCRIPTION FACTOR; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; COLON ADENOMA; COLON CARCINOGENESIS; CONTROLLED STUDY; DNA SEQUENCE; DOWN REGULATION; EMBRYO; FEMALE; GENE LOCUS; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MGLL GENE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; ONCOGENE; PDM5 GENE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FAMILY; REGULATORY MECHANISM; SMALL INTESTINE;

MURINAE; MUS;

ADENOMA; ADENOMATOUS POLYPOSIS COLI; ANIMALS; CACO-2 CELLS; CARCINOGENESIS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; DOWN-REGULATION; HUMANS; INTESTINAL NEOPLASMS; MICE; MONOACYLGLYCEROL LIPASES; MUTATION; TRANSCRIPTION FACTORS; TRANSCRIPTION INITIATION SITE; TRANSCRIPTION, GENETIC;

EID: 84908049839     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.283     Document Type: Article

References (36)

1. Fog CK, Galli GG, Lund AH. PRDM proteins: important players in differentiation and disease. Bioessays 2012; 34: 50-60.
2. Duan Z, Person RE, Lee HH, Huang S, Donadieu J, Badolato R et al. Epigenetic regulation of protein-coding and microRNA genes by the Gfi1-interacting tumor suppressor PRDM5. Mol Cell Biol 2007; 27: 6889-6902.
3. Burkitt Wright EM, Spencer HL, Daly SB, Manson FD, Zeef LA, Urquhart J et al. Mutations in PRDM5 in brittle cornea syndrome identify a pathway regulating extracellular matrix development and maintenance. Am J Hum Genet 2011; 88: 767-777.
4. Cheng HY, Chen XW, Cheng L, Liu YD, Lou G. DNA methylation and carcinogenesis of PRDM5 in cervical cancer. J Cancer Res Clin Oncol 2010; 136: 1821-1825.
5. Deng Q, Huang S. PRDM5 is silenced in human cancers and has growth suppressive activities. Oncogene 2004; 23: 4903-4910.
6. Shu XS, Geng H, Li L, Ying J, Ma C, Wang Y et al. The epigenetic modifier PRDM5 functions as a tumor suppressor through modulating WNT/beta-catenin signaling and is frequently silenced in multiple tumors. PLoS One 2011; 6: e27346.
7. Watanabe Y, Kim HS, Castoro RJ, Chung W, Estecio MR, Kondo K et al. Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. Gastroenterology 2009; 136: 2149-2158.
8. Watanabe Y, Toyota M, Kondo Y, Suzuki H, Imai T, Ohe-Toyota M et al. PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. Clin Cancer Res 2007; 13: 4786-4794.
9. Galli GG, Honnens de Lichtenberg K, Carrara M, Hans W, Wuelling M, Mentz B et al. Prdm5 regulates collagen gene transcription by association with RNA polymerase II in developing bone. PLoS Genet 2012; 8: e1002711.
10. Meani N, Pezzimenti F, Deflorian G, Mione M, Alcalay M. The tumor suppressor PRDM5 regulates Wnt signaling at early stages of zebrafish development. PLoS One 2009; 4: e4273.
11. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434: 843-850.
12. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H et al. Identification and characterization of the familial adenomatous polyposis coli gene. Cell 1991; 66: 589-600.
13. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-170.
14. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006; 127: 469-480.
15. Sansom OJ, Reed KR, Hayes AJ, Ireland H, Brinkmann H, Newton IP et al. Loss of Apc in vivo immediately perturbs Wnt signaling, differentiation, and migration. Genes Dev 2004; 18: 1385-1390.
16. Nathke IS. The adenomatous polyposis coli protein: the Achilles heel of the gut epithelium. Annu Rev Cell Dev Biol 2004; 20: 337-366.
17. Purdie CA, Harrison DJ, Peter A, Dobbie L, White S, Howie SE et al. Tumour incidence, spectrum and ploidy in mice with a large deletion in the p53 gene. Oncogene 1994; 9: 603-609.
18. Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990; 247: 322-324.
19. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng SW, Cravatt BF. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010; 140: 49-61.
20. Ye L, Zhang B, Seviour EG, Tao KX, Liu XH, Ling Y et al. Monoacylglycerol lipase (MAGL) knockdown inhibits tumor cells growth in colorectal cancer. Cancer Lett 2011; 307: 6-17.
21. Hidalgo IJ, Raub TJ, Borchardt RT. Characterization of the human colon carcinoma cell line (Caco-2) as a model system for intestinal epithelial permeability. Gastroenterology 1989; 96: 736-749.
22. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008; 7: 11-20.
23. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB. Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008; 18: 54-61.
24. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
25. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007; 7: 763-777.
26. Nomura DK, Lombardi DP, Chang JW, Niessen S, Ward AM, Long JZ et al. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem Biol 2011; 18: 846-856.
27. Bauer DE, Hatzivassiliou G, Zhao F, Andreadis C, Thompson CB. ATP citrate lyase is an important component of cell growth and transformation. Oncogene 2005; 24: 6314-6322.
28. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005; 8: 311-321.
29. Kim D, Salzberg SL. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts. Genome Biol 2011; 12: R72.
30. Roberts A, Pimentel H, Trapnell C, Pachter L. Identification of novel transcripts in annotated genomes using RNA-Seq. Bioinformatics 2011; 27: 2325-2329.
31. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat Protoc 2012; 7: 562-578.
32. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
33. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012; 9: 357-359.
34. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249-264.
35. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3: Article3.
36. Sanges R, Cordero F, Calogero RA. oneChannelGUI: a graphical interface to Bioconductor tools, designed for life scientists who are not familiar with R language. Bioinformatics 2007; 23: 3406-3408.